In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively

被引：66

作者：

Gruson, D ^{[1
]}

Pereyre, S ^{[1
]}

Renaudin, H ^{[1
]}

Charron, A ^{[1
]}

Bébéar, C ^{[1
]}

Bébéar, CM ^{[1
]}

机构：

[1] Univ Bordeaux 2, Bacteriol Lab, F-33076 Bordeaux, France

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 03期

关键词：

D O I：

10.1128/AAC.49.3.1190-1193.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Selection of resistant mutants in sequential subcultures with increasing concentrations of six and four different fluoroquinolones was studied for one reference strain each of Mycoplasma pneumoniae and Mycoplasma hominis, respectively. All fluoroquinolones tested selected for resistance, with alterations affecting the quinolone resistance-determining regions of the four target topoisomerase genes.

引用

页码：1190 / 1193

页数：4

共 13 条

[1] Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis [J].

Bebear, CM ;

Renaudin, J ;

Charron, A ;

Renaudin, H ;

de Barbeyrac, B ;

Schaeverbeke, T ;

Bebear, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :954-956

[2] Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro [J].

Bébéar, CM ;

Renaudin, H ;

Charron, A ;

Bové, JM ;

Bébéar, C ;

Renaudin, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2304-2311

[3] DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones [J].

Bébéar, CM ;

Renaudin, H ;

Charron, A ;

Clerc, M ;

Pereyre, S ;

Bébéar, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) :3323-3325

[4]

BEBEAR CM, IN PRESS MYCOPLASMAS

[5] Analysis of the gyrA and parC genes of Mycoplasma genitalium detected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment [J].

Deguchi, T ;

Maeda, SI ;

Tamaki, M ;

Yoshida, T ;

Ishiko, H ;

Ito, M ;

Yokoi, S ;

Takahashi, Y ;

Ishihara, S .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (05) :742-744

[6] Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae [J].

Himmelreich, R ;

Hilbert, H ;

Plagens, H ;

Pirkl, E ;

Li, BC ;

Herrmann, R .

NUCLEIC ACIDS RESEARCH, 1996, 24 (22) :4420-4449

[7]

Hooper D. C., 2003, QUINOLONE ANTIMICROB, P41, DOI DOI 10.1128/9781555817817.CH3

[8] Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations [J].

Kenny, GE ;

Young, PA ;

Cartwright, FD ;

Sjöström, KE ;

Huang, WM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) :2493-2496

[9] Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae [J].

Nagai, K ;

Davies, TA ;

Dewasse, BE ;

Jacobs, MR ;

Appelbaum, PC .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (03) :365-374

[10] In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae [J].

Pereyre, S ;

Guyot, C ;

Renaudin, H ;

Charron, A ;

Bébéar, C ;

Bébéar, CM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (02) :460-465

← 1 2 →